Pursued progress while ensuring stability and built up momentum, Legend Holdings realized revenue of RMB237,685 million in the first half of 2022

HONG KONG, Aug 31, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Holdings Corporation (stock code: 3396.HK) announced today the unaudited condensed consolidated interim results for the six months ended June 30, 2022 (the "Reporting Period"). During the Reporting Period, the Company's revenue was RMB237,685 million and the net profit...

Legend Capital Super Antibiotic Portfolio Company: Scarce Enterprise MicuRx Pharmaceuticals is Listed on the STAR Market Successfully

HONG KONG, Aug 9, 2022 - (ACN Newswire via SEAPRWire.com) - On August 5, 2022, Legend Capital portfolio company MicuRx Pharmaceuticals, a scarce enterprise in super antibiotic, was successfully listed on the STAR Market. MicuRx Pharmaceuticals issued 130,000,000 shares this time, accounting for 19.84% of the total share capital after...

Breakthrough Cooperation of Legend Capital’s Cross-border Portfolio Companies: Innovent and Etana Jointly Announce the Approval of Bevagen by the BPOM

HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - On June 14, two of Legend Capital's portfolio companies, Innovent Biologics, Inc. ("Innovent") and PT Etana Biotechnologies Indonesia ("Etana"), jointly announced that the Indonesian Food and Drugs Authority (BPOM) had approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal...

Legend Capital’s Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China

HONG KONG, Apr 24, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics, announced that the clinical trial application of its product LX101 injection for the treatment of patients with Rpe65 biallelic mutation-associated inherited retinal degenerations (IRD) was...